Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.Citation formats

  • Authors:
  • Eric D Bateman
  • Eugene R Bleecker
  • Jan Lötvall
  • Ashley Woodcock
  • Richard Forth
  • And 5 others
  • External authors:
  • Hilary Medley
  • Angela M Davis
  • Loretta Jacques
  • Brett Haumann
  • William W Busse

Standard

Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. / Bateman, Eric D; Bleecker, Eugene R; Lötvall, Jan; Woodcock, Ashley; Forth, Richard; Medley, Hilary; Davis, Angela M; Jacques, Loretta; Haumann, Brett; Busse, William W.

In: Respiratory Medicine, Vol. 106, No. 5, 05.2012.

Research output: Contribution to journalArticle

Harvard

Bateman, ED, Bleecker, ER, Lötvall, J, Woodcock, A, Forth, R, Medley, H, Davis, AM, Jacques, L, Haumann, B & Busse, WW 2012, 'Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.' Respiratory Medicine, vol. 106, no. 5. https://doi.org/10.1016/j.rmed.2012.01.004

APA

Bateman, E. D., Bleecker, E. R., Lötvall, J., Woodcock, A., Forth, R., Medley, H., ... Busse, W. W. (2012). Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respiratory Medicine, 106(5). https://doi.org/10.1016/j.rmed.2012.01.004

Vancouver

Bateman ED, Bleecker ER, Lötvall J, Woodcock A, Forth R, Medley H et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respiratory Medicine. 2012 May;106(5). https://doi.org/10.1016/j.rmed.2012.01.004

Author

Bateman, Eric D ; Bleecker, Eugene R ; Lötvall, Jan ; Woodcock, Ashley ; Forth, Richard ; Medley, Hilary ; Davis, Angela M ; Jacques, Loretta ; Haumann, Brett ; Busse, William W. / Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. In: Respiratory Medicine. 2012 ; Vol. 106, No. 5.

Bibtex

@article{64ff9a7d16b8460fb532259d60b564c0,
title = "Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.",
abstract = "BACKGROUND: This randomized, double-blind, multicenter study was designed to evaluate the efficacy of inhaled once-daily fluticasone furoate (FF) administered in the evening in patients with persistent asthma not controlled by short-acting beta(2) agonists, and to determine the dose(s) suitable for further development. METHODS: Of 1459 patients screened, 598 received one of six treatments: placebo, FF (25 μg, 50 μg, 100 μg or 200 μg) once daily each evening, or fluticasone propionate (FP) 100 μg twice daily for 8 weeks. The primary endpoint was change from baseline in pre-dose evening forced expiratory volume in 1 s (FEV(1)). RESULTS: A dose-response effect was observed for once-daily FF 25-200 μg including (p <0.001) and excluding placebo (p = 0.03). FF 50-200 μg once daily significantly increased FEV(1) from baseline (p <0.05 vs placebo), by >200 mL for FF 100 μg and 200 μg. Significant improvements were also achieved for peak expiratory flow, and percentage symptom-free and rescue-free 24 h periods. The magnitude of effect was at least as good as twice-daily FP. Overall, once-daily FF was well tolerated with no systemic corticosteroid effects. CONCLUSION: FF 50-200 μg/day once daily in the evening demonstrated dose-related efficacy in asthma with 100-200 μg appearing to be the optimal doses for further evaluation. ClinicalTrials.gov: NCT00603382.",
author = "Bateman, {Eric D} and Bleecker, {Eugene R} and Jan L{\"o}tvall and Ashley Woodcock and Richard Forth and Hilary Medley and Davis, {Angela M} and Loretta Jacques and Brett Haumann and Busse, {William W}",
year = "2012",
month = "5",
doi = "10.1016/j.rmed.2012.01.004",
language = "English",
volume = "106",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Co. Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.

AU - Bateman, Eric D

AU - Bleecker, Eugene R

AU - Lötvall, Jan

AU - Woodcock, Ashley

AU - Forth, Richard

AU - Medley, Hilary

AU - Davis, Angela M

AU - Jacques, Loretta

AU - Haumann, Brett

AU - Busse, William W

PY - 2012/5

Y1 - 2012/5

N2 - BACKGROUND: This randomized, double-blind, multicenter study was designed to evaluate the efficacy of inhaled once-daily fluticasone furoate (FF) administered in the evening in patients with persistent asthma not controlled by short-acting beta(2) agonists, and to determine the dose(s) suitable for further development. METHODS: Of 1459 patients screened, 598 received one of six treatments: placebo, FF (25 μg, 50 μg, 100 μg or 200 μg) once daily each evening, or fluticasone propionate (FP) 100 μg twice daily for 8 weeks. The primary endpoint was change from baseline in pre-dose evening forced expiratory volume in 1 s (FEV(1)). RESULTS: A dose-response effect was observed for once-daily FF 25-200 μg including (p <0.001) and excluding placebo (p = 0.03). FF 50-200 μg once daily significantly increased FEV(1) from baseline (p <0.05 vs placebo), by >200 mL for FF 100 μg and 200 μg. Significant improvements were also achieved for peak expiratory flow, and percentage symptom-free and rescue-free 24 h periods. The magnitude of effect was at least as good as twice-daily FP. Overall, once-daily FF was well tolerated with no systemic corticosteroid effects. CONCLUSION: FF 50-200 μg/day once daily in the evening demonstrated dose-related efficacy in asthma with 100-200 μg appearing to be the optimal doses for further evaluation. ClinicalTrials.gov: NCT00603382.

AB - BACKGROUND: This randomized, double-blind, multicenter study was designed to evaluate the efficacy of inhaled once-daily fluticasone furoate (FF) administered in the evening in patients with persistent asthma not controlled by short-acting beta(2) agonists, and to determine the dose(s) suitable for further development. METHODS: Of 1459 patients screened, 598 received one of six treatments: placebo, FF (25 μg, 50 μg, 100 μg or 200 μg) once daily each evening, or fluticasone propionate (FP) 100 μg twice daily for 8 weeks. The primary endpoint was change from baseline in pre-dose evening forced expiratory volume in 1 s (FEV(1)). RESULTS: A dose-response effect was observed for once-daily FF 25-200 μg including (p <0.001) and excluding placebo (p = 0.03). FF 50-200 μg once daily significantly increased FEV(1) from baseline (p <0.05 vs placebo), by >200 mL for FF 100 μg and 200 μg. Significant improvements were also achieved for peak expiratory flow, and percentage symptom-free and rescue-free 24 h periods. The magnitude of effect was at least as good as twice-daily FP. Overall, once-daily FF was well tolerated with no systemic corticosteroid effects. CONCLUSION: FF 50-200 μg/day once daily in the evening demonstrated dose-related efficacy in asthma with 100-200 μg appearing to be the optimal doses for further evaluation. ClinicalTrials.gov: NCT00603382.

U2 - 10.1016/j.rmed.2012.01.004

DO - 10.1016/j.rmed.2012.01.004

M3 - Article

VL - 106

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 5

ER -